VIM and hepatocellular carcinoma: Furthermore, SIRT5 directly binds Vimentin, which, in more metastatic HCC phenotypes, shows an acetylation site on K120, which could be a target for SIRT5 activity, enhancing the metastatic process in HCC [225].